Aflibercept 8mg in Neovascular AMD and DMO: Insights from PULSAR and PHOTON Trials
home / rapid-readouts / aflibercept-8mg-in-neovascular-amd-and-dmo-insights-from-pulsar-and-photon-trials
Dr. Marion Munk reviews clinical trials of high-dose aflibercept in neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO), providing insights and discussing the clinical implications derived from these trials.
EP. 1: Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD
May 6th 2024Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.
